A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL
Status:
Terminated
Trial end date:
2016-11-16
Target enrollment:
Participant gender:
Summary
This dose-escalation study is designed for determining the safety, tolerability,
pharmacokinetics (PK), biological, and clinical activity of DI-Leu16-IL2 administered to
participants with cluster of differentiation 20 (CD20) positive NHL that have failed standard
rituximab-containing therapy.